Neurological Biomarkers Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, China - Size and Forecast 2024-2028

Neurological Biomarkers Market Forecast 2024-2028

The global neurological biomarkers market size is estimated to grow by USD 7.82 billion at a CAGR of 13.01% between 2023 and 2028. 

The globalization of clinical trials has consistently expanded over the past two decades, which has been credited to numerous components, including organized trials, voluntary members, accessibility of qualified local investigators, improved infrastructure facilities, and the low expense of clinical trials in developing nations. The potential clinical advantages for disease-specific biomarkers incorporate faster and more accurate disease analysis and potential diminishing in sample size and time of clinical trials, which will accelerate drug development. The use of biomarkers in the clinical field of neurological disorders is expected to figure out whether a medication achieves its proposed target or changes the course of the disease. Both the US FDA and the European Medicines Agency (EMA) perceive an essential role of biomarkers in the medication improvement process. Thus, the increase in clinical trials will drive the growth of the global neurological biomarkers market during the forecast period.

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by End-user, Indication and Geography Analysis

End-user Analysis

The market share growth by the hospitals segment will be significant during the forecast period. Hospitals are the key end-users of neurological biomarkers, which greatly influence market growth. Large hospitals such as multispecialty hospitals and hospital groups work under government sponsorship or through funding from private entities and have more than 500 hospital beds, allowing the accommodation of individuals within the facility

Get a glance at the market contribution of various segments Download PDF Sample

The hospitals segment was the largest and was valued at USD 2.18 billion in 2018. Medium-sized hospitals have a limited number of supplier groups. These hospitals often require outsourced medical equipment and laboratory testing support for their healthcare services. Their budget is limited as the facility has 200-300 hospital beds. The administration of these hospitals is often decentralized. Medium-sized hospitals are more in number when compared to large hospitals, so they are easily accessible to people. Such factors are expected to increase the sales of neurological biomarker products in medium-sized hospitals, which will thereby drive the growth of the hospital segment and expand the growth of the market during the forecast period.

End-user Analysis

Alzheimer's disease (AD) is a brain disorder that destroys memory and thinking skills and, eventually, the ability to carry out simple tasks. The diagnostic guidelines of AD have been redesigned to incorporate the use of brain imaging and CSF biomarkers to check whether an individual has a progressing AD neuropathological process. Neurobiological biomarkers are an effective tool for early detection of AD, and they indicate progressive development before the main manifestations of the disease. There are three distinct phases of AD, which are pre-clinical AD, mild cognitive impairment (MCI) caused by AD, and AD with dementia. Scientists are now looking into whether interventions aimed at restoring a gut microbiome could help slow down or prevent the progression of AD. Investigations are paving the way for treatments to combat this debilitating condition. The abovementioned factors are expected to drive the growth of the AD segment and will propel the growth of the global neurological biomarkers market during the forecast period.

Parkinson's disease (PD) is a brain disorder that causes unintended or uncontrollable movement, such as shaking, stiffness, and difficulty with balance and coordination. The Symptoms of PD begin gradually and worsen over time. With the increasing span of time, people with PD may have difficulty walking and talking. Thus, PD is a recognizable clinical syndrome with a range of causes and clinical conditions. PD represents a fast-growing neurodegenerative condition. Various dopamine presynaptic biomarkers such as dopamine transporter (DAT) or vesicular monoamine transporter type 2 can be identified by single-photon emission computed tomography (SPECT), which could fulfill the requirement of being a useful biomarker for the treatment of PD. Thus, the development of such techniques under the Parkinsons disease segment will positively impact the growth of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and drivers will shape the market during the forecast period. The increasing demand for the diagnosis of neurological disorders has boosted the demand for neurological biomarkers. For instance, an estimated 6.2 million Americans aged 65 and older lived with Alzheimers dementia in March 2021. The number could grow to 13.8 million by 2060. Also, official death certificates recorded 121,499 deaths from AD in 2019, making Alzheimers the sixth-leading cause of death in the US and the fifth-leading cause of death among Americans aged 65 and older. Thus, the high prevalence of neurological disorders, the growing aging population, high healthcare expenditure on the treatment of neurological diseases, and favorable reimbursement policies for neuro-diagnostic procedures are expected to drive market.

In addition, the bioscience research expenditure has grown in the US and Canada. For instance, the Canadian budget for 2021 doubled down on progress made to provide USD2.2 billion toward implementing the biomanufacturing and life sciences strategy. The funding from different societies and private organizations promotes the US and Canada to focus on drug discovery and development for neurological disorders using neurological biomarkers, which will positively impact the global neurological biomarkers market during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abbott Laboratories - The company offeres neurological biomarkers namely I STAT Alinity, an easy to use, portable blood analyzer that delivers real time, lab quality diagnostic test results.

• ACROBIOSYSTEMS INC.
• Advanced Brain Monitoring Inc.
• Alseres Pharmaceuticals In
• Bio Rad Laboratories Inc.
• bioMerieux SA
• Charles River Laboratories International Inc.
• EATRIS ERIC
• Eli Lilly and Co.
• Enzo Biochem Inc.
• F. Hoffmann La Roche Ltd.
• Fujirebio Holdings Inc.
• IQVIA Holdings Inc.
• Merck KGaA
• Metabolon Inc.
• PerkinElmer Inc
• Proteome Sciences plc
• QIAGEN NV
• Quanterix Corp.,
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics 

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Drivers

Increasing initiatives and support from governments to improve neurological healthcare access is notably driving market growth. Governments and healthcare organizations are actively working to enhance access to healthcare for individuals with neurological disorders through various initiatives. The World Health Organization collaborates with partners to improve care for individuals with epilepsy, and the Mental Health Innovation Network focuses on treating epileptic patients while combating stigma in Asia. The Welsh Government is dedicated to enhancing access to care for neurological conditions like epilepsy, cerebral palsy, and Parkinson's disease in Wales, emphasizing swift diagnosis, effective care, awareness, information improvement, and supportive research.

Moreover, initiatives like the Brain Donor Project seek funding to advance sciences for neurological disorder treatments, while the National Institute of Health's COVID-19 Neuro Databank/Biobank database tracks neurological symptoms associated with COVID-19. Increased public spending on neurological diseases, coupled with research efforts by institutions like the National Institute of Neurological Disorders and Stroke, is expected to drive the market's growth in the forecast period. 

Significant  Trends

The growing availability of blood-based biomarkers is an emerging trend shaping market growth. Neurodegenerative disorders such as AD are a public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of pathophysiology play a crucial role in research, clinical trials, and the clinical work-up of the patients. In Alzheimers disease, breakthroughs in biomarker identification and validation include cerebrospinal fluid of amyloid-beta and tau proteins, which are highly accurate in detecting the presence of pathophysiological and neuropathological changes. Thus, fluid biomarkers, especially plasma-based biomarkers, are attractive as they are non-invasive and easy to obtain.

Also, emerging blood biomarkers, including amyloid beta monomers, oligomers, tau/p-tau, neurofilament light chain, and inflammatory factors, are gathering tremendous research interest. As a result of rapid advances in the development of ultrasensitive assays, the levels of pathological brain- and AD-related proteins can be measured in blood. Thus, blood-based biomarkers are emerging as an important tool to detect TBIs, which will drive the growth of the market during the forecast period.

Major  Challenges

Inherent challenges in neurological research are a significant challenge hindering market growth. The shift of biomarkers from discovery to clinical practice is a complex procedure. The main challenges include stringent validation strategies and moderate progression of the disease, requiring a high number of patients to experience long-haul treatment when traditional diagnostic parameters are utilized. Since the rise of the supposed innovation, various biomarkers have been distinguished and published, which have expanded the options for growth in the availability of more viable therapeutics. These opportunities are expected to have a significant impact on the financial aspects of healthcare services in the long term.

Furthermore, as for European neuroscientists, there is a disconnect between the growing socioeconomic need for effective therapies for brain disorders and the lack of ambition and long-term vision of neurological research in Europe. Thus, the lack of neurological research globally is expected to hinder the growth of the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• End-user Outlook
  • Hospitals
  • Clinical diagnostic centers
  • Research organizations and others

• Indication Outlook
  • AD
  • PD
  • ASD
  • MS
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • South America
    • Chile 
    • Brazil
    • Argentina 
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Argentina
    • Brazil
    • Rest of the World

Market Analyst Overview 

The Neurological Biomarkers Market, crucial in understanding brain-related disorders, witnesses advancements. Recognized by WHO, it spans conditions like autism, major depressive disorder, and chronic traumatic encephalopathy. Blood-Based Biomarkers (BBBMs) play a pivotal role, with NIH contributing through antigen-antibody binding techniques. Sleep biomarkers and CNS markers, including Neurofilament Light Protein (NfL), are vital.

The University of North Texas Health Science Center contributes insights, focusing on sample storage, processing procedures, collection methods, and assay standardization. The Alzheimer's Precision Medicine Initiative leads to competitive benchmarking, leveraging historical data, forecasts, and company revenue shares. Proteomic biomarkers, SMCxPRO, and digital biomarkers mark the latest trends, with the National Institute of Neurological Disorders and Stroke and healthcare infrastructure playing essential roles in regional opportunities.

Neurological Biomarkers Market Scope
Report Coverage	Details
Page number	175
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 13.01%
Market Growth 2024-2028	USD 7.82 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	12.2
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 40%
Key countries	US, Germany, UK, France, and China
Competitive landscape	Leading Companies, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market growth analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution n of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch